Filing Flows › Altimmune (ALT) › Q4 2025 › vs Q4 2024
Altimmune (ALT) Q4 2025 vs Q4 2024 (year over year)
Altimmune's revenue rose $21K (+420%) from $5K in Q4 2024 to $26K in Q4 2025.
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $26K | $5K | $21K | +420% |
| Other income, net | $1.5M | $1.7M | −$151K | -9% |
| Net loss | $27.4M | $23.2M | $4.2M | +18% |
| Costs & expenses | $28.9M | $24.9M | $4.0M | +16% |
| Operating costs | $28.9M | $24.9M | $4.0M | +16% |
| Research & development | $18.4M | $19.8M | −$1.4M | -7% |
| General & admin | $10.5M | $5.1M | $5.4M | +106% |
| Operating cash sources | $27.4M | $23.2M | $4.2M | +18% |
| Depreciation | $26K | $33K | −$7K | -21% |
| Share-based compensation | $4.9M | $3.4M | $1.6M | +47% |
| Working capital & other | $2.9M | $1.5M | $1.4M | +93% |
| Cash used in operations | $19.4M | $18.3M | $1.2M | +6% |
| Net loss absorbed | $27.4M | $23.2M | $4.2M | +18% |
Questions
How much did Altimmune's revenue grow year over year in Q4 2025?
Altimmune's revenue rose $21K (+420%) from $5K in Q4 2024 to $26K in Q4 2025.